【摘要】 目的　观察13 1Ⅰ标记肝癌单克隆抗体Hepama治疗晚期肝癌的疗效。方法　采用13 1Ⅰ -Hepama - 1单克隆抗体周转静脉注射治疗 2 8例失去手术时机的晚期肝癌患者。结果　多数患者癌性症状减轻 ,生活质量提高 ,CR +PR +MR率为 4 6 4 % (13/ 2 8) ,1年生存率 2 1 4 % (6 / 2 8) ,且对人体肾功能及甲状腺功能无明显影响(P>0 .0 5 )。结论　13 1Ⅰ -Hepama- 1周围静脉注射治疗晚期肝癌 ,疗效肯定 ,方法简便安全 ,不良反应轻 ,可作为晚期肝癌治疗方法之一 ,值得进一临床应用与观察更多还原

【Abstract】 Objective To evaluate 131Ⅰ-Hepama-1 monoclonal antibody targeting therapy in advanced liver cancer. Methods 28 patients with advanced liver cancer were treated with 131Ⅰ-Hepama-1 monoclonal antibody injected into the peripheral veins.Results Improvement of symptoms and signs were observed in most of the treated patients in addition to improvement of quality of life.The over-all rate of CR+PR+MR was 46.4% (13/28),and the 1-year survival rate was 21.4%(6/28),and was no side effects for kidney and thyroid gland function test(P>0.05).Conclusion The targeting therapy with 131I-Hepama-1 monoclonal antibody provided high effectiveness,less side-effects and worth futher study.更多还原